Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

This study has been terminated.
(Poor enrollment)
Sponsor:
Collaborators:
Abbott
Pfizer
Information provided by (Responsible Party):
Stephanie Brictson, Temple University
ClinicalTrials.gov Identifier:
NCT01068873
First received: February 12, 2010
Last updated: June 5, 2014
Last verified: June 2014

February 12, 2010
June 5, 2014
April 2010
June 2014   (final data collection date for primary outcome measure)
Assess proportion of participants with HIV RNA levels <50 and < 400 copies/mL. [ Time Frame: week 48 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01068873 on ClinicalTrials.gov Archive Site
  • Assess proportion of participants with HIV RNA < 50 and <400 copies/ml. [ Time Frame: week 24 ] [ Designated as safety issue: No ]
  • Assess the proportion of participants at study termination with VL < 50 copies/ml. [ Time Frame: week 48 ] [ Designated as safety issue: No ]
  • Determine the time to viral suppression (VL < 50 copies/ml). [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Determine the median change in VL from baseline to week 24, to week 48 and to study termination. [ Time Frame: week 24, week 48 ] [ Designated as safety issue: No ]
  • Assess the changes in CD4+ T cell count. [ Time Frame: week 24, 48 ] [ Designated as safety issue: No ]
  • Assess development of HIV resistance mutations and in HIV co-receptor tropism changes in participants who develop virologic rebound. [ Time Frame: week 48 ] [ Designated as safety issue: No ]
  • Assess safety and tolerability including any lipid changes. [ Time Frame: week 48 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Kaletra and Maraviroc in Antiretroviral Therapy-Naïve Patients - KALMAR Study -Version 1.0 Amendment 2

The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty patients will be enrolled and studied for 48 weeks.

As patients with HIV are living longer it is important to explore antiretroviral treatments which may reduce the development of long term complications while preserving future HIV treatment options. This trial explores an antiretroviral treatment regimen which does not include the nucleoside reverse transcriptase inhibitor class which is thought to have long-term toxicity. This is a non-randomized, open label trial in participants meeting entry requirements.

Participants will be evaluated at screening, baseline,and weeks 4, 8, 12, 24, 36, and 48 to include clinical assessments as well as laboratory assessments.

An interim analysis will be performed when all patients have reached the week 24 visit.

Interventional
Phase 4
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
Drug: lopinavir/ritonavir plus maraviroc
Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
Other Names:
  • Lopinavir/ritonavir (Kaletra)
  • Maraviroc (Selzentry)
  • Nucleoside sparing regimen
Experimental: open label single arm
Drug: lopinavir/ritonavir plus maraviroc
Intervention: Drug: lopinavir/ritonavir plus maraviroc
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient has signed and dated approved informed consent form.
  • There is confirmed laboratory diagnosis of HIV infection (positive ELISA HIV antibody test confirmed by Western blot, p24 antigen assay, quantitative HIV-1 RNA assay, or HIV culture).
  • The patient is at least 18 years of age.
  • ART-naïve, lopinavir/ritonavir susceptible on genotypic testing, CCR5-tropic virus on Trofile testing (ESTA).
  • Negative pregnancy test within 72 hours prior to start of study for women of childbearing potential.
  • Females of childbearing potential and males must utilize effective barrier contraception.
  • HIV RNA greater than 1,000 copies per mL at entry.
  • Liver enzymes (AST, ALT) < 3 times the upper limit of normal.

Exclusion Criteria:

  • Patients who are pregnant or breast-feeding.
  • Active alcohol or substance abuse sufficient, in the Investigator's opinion that makes compliance to the study protocol unlikely.
  • Suspected or active HIV-related opportunistic infection or condition requiring acute therapy within 30 days of entry into the trial.
  • Patients on therapy for hepatitis B.
  • Patients with hepatitis B surface antigen, or any evidence of active hepatitis B such as positive hepatitis B DNA and/or presence of hepatitis e antigen or e antibody.
  • Acute hepatitis B or C within 60 days of entry.
  • Patients harboring preexistent co-receptor CXCR4 tropic or dual-or mixed-tropic HIV.
  • Patients harboring HIV resistant to lopinavir/ritonavir on genotypic testing.
  • The presence of decompensated heart failure, myocardial infarction within 1 year, bypass surgery, severe vascular disease, or active hepatobiliary disease.
  • Concomitant use of rifampin, ergot derivatives (i.e. dihydroergotamine, ergotamine), cisapride, lovastatin, simvastatin, triazolam, orally administered midazolam, carbamazepine, phenytoin, St. John's wort, ketoconazole, itraconazole, clarithromycin, telithromycin, amiodarone, bepridil, flecainide, propafenone, quinidine, voriconazole or nefazodone.
  • Patients with concomitant diagnosis of malignancy or cancer other than basal cell carcinoma within the past 5 years.
  • Concomitant use of investigational agents including the use of any investigational vaccines.
  • Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for study, or unable to comply with the dosing requirements.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01068873
Temple IRB 12848
No
Stephanie Brictson, Temple University
Temple University
  • Abbott
  • Pfizer
Principal Investigator: Mary van den Berg-Wolf, MD Temple University
Temple University
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP